Literature DB >> 11013902

Thyroid cancer: patients' experiences of receiving iodine-131 therapy.

K I Stajduhar1, J Neithercut, E Chu, P Pham, J Rohde, A Sicotte, K Young.   

Abstract

PURPOSE/
OBJECTIVES: To enhance understanding of the experiences and educational needs of patients receiving iodine-131 (131I) therapy for the treatment of thyroid cancer.
DESIGN: Qualitative design using interpretive description.
SETTING: A 24-bed oncology/acute-care medical unit in a large tertiary hospital in western Canada. SAMPLE: 5 men and 22 women (18-80 years of age) who have received 131I therapy in the past two years.
METHODS: Unstructured focus group and telephone interviews and field notes. Interviews were tape-recorded, transcribed verbatim, and subjected to thematic analysis.
FINDINGS: Researchers elicited four major themes from the analysis: (a) recognizing the totality of the cancer experience, (b) being isolated, (c) recognizing the totality of the treatment experience, and (d) understanding barriers to treatment.
CONCLUSIONS: Healthcare providers require a better understanding of thyroid disease and the treatment and side effects of 131I therapy. Furthermore, educational programs are required to adequately prepare nurses and patients for future care. IMPLICATIONS FOR NURSING PRACTICE: A need exists to improve the care and education provided to patients receiving 131I therapy. In particular, recognition of the totality of the cancer experience and the need for both staff and patient education were illustrated. If nurses are to provide comprehensive cancer care, both psychosocial and physical needs must be addressed and fulfilling these needs requires a collaborative approach among patients, nurses, and other healthcare professionals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11013902

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  9 in total

1.  Health-related Quality of Life, depression and anxiety in thyroid cancer patients.

Authors:  Sefik Tagay; Stephan Herpertz; Matthias Langkafel; Yesim Erim; Andreas Bockisch; Wolfgang Senf; Rainer Görges
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

2.  A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases.

Authors:  Katy Gallop; Cicely Kerr; Stacey Simmons; Bryan McIver; Ezra E W Cohen
Journal:  Qual Life Res       Date:  2014-08-09       Impact factor: 4.147

3.  Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.

Authors:  G Berg; G Lindstedt; M Suurküla; S Jansson
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

4.  Quality of life after thyroid cancer: an assessment of patient needs and preferences for information and support.

Authors:  Katherine J Roberts; Stephen J Lepore; Mark L Urken
Journal:  J Cancer Educ       Date:  2008       Impact factor: 2.037

5.  Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.

Authors:  Bae P Chu; Christopher Horan; Ellen Basu; Lawrence Dauer; Matthew Williamson; Jorge A Carrasquillo; Neeta Pandit-Taskar; Shakeel Modak
Journal:  Pediatr Blood Cancer       Date:  2016-01-15       Impact factor: 3.167

Review 6.  Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature.

Authors:  Adem Sav; Asiyeh Salehi; Frances S Mair; Sara S McMillan
Journal:  BMC Med Res Methodol       Date:  2017-09-12       Impact factor: 4.615

7.  Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress.

Authors:  Guoyu Wang; Juhua Zhuang; Jing Ni; Ying Ye; Saifei He; Wei Xia
Journal:  Exp Ther Med       Date:  2018-08-23       Impact factor: 2.447

8.  Experiences of Korean patients with thyroid cancer receiving radioactive iodine therapy after total thyroidectomy.

Authors:  Jeong Ha Shin; Shin-Young Lee
Journal:  Asia Pac J Oncol Nurs       Date:  2021-12-25

9.  Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer.

Authors:  Beth A Fordham; Cicely Kerr; Hayley M de Freitas; Andrew J Lloyd; Karissa Johnston; Corey L Pelletier; Gabriel Tremblay; Anna Forsythe; Bryan McIver; Ezra Ew Cohen
Journal:  Patient Prefer Adherence       Date:  2015-11-03       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.